B-Cell Lymphoma 2 Inhibition in Acute Lymphoblastic Leukemia: Mechanisms, Resistance, and Emerging Combinations With Venetoclax [0.03%]
急性淋巴细胞白血病中B细胞淋巴瘤2抑制：机制、耐药性及与维奈克拉联合用药的新进展
Amr Hanbali,Ahmed Kotb,Mostafa Saleh
Amr Hanbali
Recent studies show that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax is a promising therapeutic drug for acute lymphoblastic leukemia (ALL), especially in high-risk subtypes including early T-cell precursor (ETP)-ALL, Philadelphia ch...
Beyond the Blood Cell: The Emerging Role of Cell-Free DNA in Transfusion Medicine [0.03%]
超越血细胞：游离DNA在输血医学中作用初探
Jackson M Wahman,Rhoda X Hijazi,Elizabeth Duncan et al.
Jackson M Wahman et al.
Cell-free DNA (cfDNA) consists of fragmented nuclear and mitochondrial DNA circulating in the bloodstream, primarily originating from hematopoietic cells. While cfDNA analysis has transformed diagnostic medicine, its presence in transfused ...
Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes [0.03%]
妈妈洛替尼治疗骨髓纤维化疗效和安全性的系统评价和荟萃分析：聚焦贫血相关结局
Jowan Al-Nusair,Mo&#x;men Aldalal&#x;ah,Mohammad Alqudah et al.
Jowan Al-Nusair et al.
Background: Myelofibrosis (MF) can be primary (PMF) or secondary (SMF), with PMF driven by Janus kinases-signal transducer and activator of transcription proteins (JAK-STAT) pathway activation due to Janus kinase 2 (JAK2)...
Novel Red Blood Cell Exchange Parameters for Treatment of Transfusion-Dependent Thalassemia Based on Experience of Five Patients [0.03%]
基于5例患者的治疗经验用于输血依赖性地中海贫血红细胞交换新模式参数
Kristina Sevcik,Claire Jackson,Shelly M Williams et al.
Kristina Sevcik et al.
Background: Thalassemias are inherited red blood cell disorders characterized by defective globin production, resulting in microcytic hypochromic anemia. Severe variants lead to transfusion dependence and consequent iron ...
Light Chain (AL) Amyloidosis Masquerading as Scleroderma: A Diagnostic Challenge [0.03%]
以硬皮病为表现的AL轻链型淀粉样变性：一种诊断挑战
Kriti Dhamija,Rahim A Jiwani,Arjun Lakshaman et al.
Kriti Dhamija et al.
Systemic amyloidosis has diverse, often nonspecific, clinical manifestations that overlap or mimic other medical disorders, making amyloidosis a diagnostic challenge. We present a case of a middle-aged female who presented with skin thicken...
Case Reports
Journal of hematology. 2025 Jun;14(3):152-157. DOI:10.14740/jh2055 2025
Hairy Cell Leukemia With Splenic Rupture: Hematological Changes and Disappearance of Hairy Morphology After Splenectomy [0.03%]
脾破裂的毛细胞白血病的血液学变化及脾切除术后形态消失
Stanley Kim,Anna Mikami,William Stull
Stanley Kim
We present the case of a 64-year-old man who suffered a splenic rupture following a fall. A peripheral blood smear showed mononuclear cells with "hairy" cytoplasmic projections. A computed tomography (CT) angiogram revealed splenomegaly wit...
Case Reports
Journal of hematology. 2025 Jun;14(3):139-145. DOI:10.14740/jh2045 2025
Efficacy of Short-Course High-Dose Oral Prednisolone in Rapid Platelet Recovery for Pediatric Acute Immune Thrombocytopenic Purpura: A Prospective Cohort Study [0.03%]
短期大剂量口服泼尼松龙治疗儿童急性免疫性血小板减少性紫癜的止血效应：前瞻性队列研究
Akshat Jhingan,Neha Goel,Amitabh Singh et al.
Akshat Jhingan et al.
Background: Standard management of acute immune thrombocytopenic purpura (ITP) remains debated, with some advocating observation for mild cases, while others recommend pharmacological intervention to accelerate platelet r...
Differential MicroRNA Profiles Associated With the Hydroxyurea-Inducible SAR1A Gene [0.03%]
与羟基脲诱导的SAR1A基因相关的差异微小RNA谱型
Chutima Kumkhaek,Jianqiong Zhu,Wulin Aerbajinai et al.
Chutima Kumkhaek et al.
Inflammatory Cytokines in Association With High Fetal Hemoglobin Level Reduce the Episodes of Vaso-Occlusive Crisis in Sickle Cell Patients [0.03%]
高水平胎儿血红蛋白与炎症细胞因子减少镰形细胞性贫血患者的急性发作次数相关性研究
Sujata Dixit,Arundhuti Das,Priyanka Samal et al.
Sujata Dixit et al.
Background: Vaso-occlusive crisis (VOC), a common clinical manifestation of sickle cell disease (SCD), is mediated by a series of inflammatory responses. Conversely, a high fetal hemoglobin (Hb F) level is a known factor ...
Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma [0.03%]
鲁索利替尼可有效治疗多发性骨髓瘤患者卡比妥卡博泰仑相关的帕金森综合征
Baldeep Wirk,Jin Lim
Baldeep Wirk
After ciltacabtagene autoleucel (cilta-cel) in multiple myeloma, 5% of patients can develop parkinsonism, with a high fatality rate. The pathogenesis and optimal therapy of parkinsonism from B-cell maturation antigen chimeric antigen recept...
Case Reports
Journal of hematology. 2025 Jun;14(3):146-151. DOI:10.14740/jh2046 2025